Clinical trials: AD-MCI
Mild Cognitive Impairment, Alzheimer Disease (AD)
Microbiome in Aging of Gut and Brain
The Microbiome in Aging Gut and Brain (MiaGB) Study is an observational study designed to examine whether differences in the microorganisms living in the gut and mouth are associated with cognitive health and cognitive decline.
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease (AD), Dementia
- Trial name
- MiaGB (NCT07799402)
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Alzheimer Disease, Aging
Bilateral Brain Dynamics in Cognition and Aging
This project is focused on the gap in understanding of bilateral brain interactions and their role in helping normative and clinical elderly populations maintain cognitive health.
- Conditions
- Alzheimer Disease, Aging, MCI
- Trial name
- NCT03224988
- Testing
- TMS
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Duke University
Dry Age Related Macular Degeneration, Mild Cognitive Impairment (MCI)
Study to Detect Dendritic Cell Recruitment in Human Retina
The goal of this study is to develop an optimal method to detect the immune cells (cells that protect the human body against diseases) in association with abnormal conditions of the retina (light sensitive tissue in the back of…
- Conditions
- Dry Age Related Macular Degeneration, Mild Cognitive Impairment (MCI), Alzheimer Disease
- Trial name
- ICG-002 (NCT06872658)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- MindImmune Therapeutics, Inc.
Dementia, Early Onset, Alzheimer Dementia (AD)
Genetic Studies of Early-onset Dementia
The aim of this study is to identify genetic factors that contribute to risk and progression of early-onset dementia (loss of memory function before the age of 70 years) across all ethnic groups, including Alzheimer's Disease…
- Conditions
- Dementia, Early Onset, Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI), Memory Loss
- Trial name
- NCT04906863
- Testing
- Blood draw, Neurocognitive testing, Medical questionnaire
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Columbia University
MCI-AD, Early Stage Alzheimer's Disease
Development of a Novel Multidimensional Therapeutic Intervention Protocol for MCI
As populations age, Alzheimer's disease (AD) is increasing while disease-modifying drugs remain elusive, making early diagnosis and intervention essential.
- Trial name
- NCT07196592
- Testing
- Olfactory stimulation, Temporal Interference,TI, Olfactory-TI Stimulation
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Yuan Shen
Mild Cognitive Impairment (MCI)
Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)
This research is being done to find out if daily use of the drug levetiracetam can improve memory function in individuals with memory problems like those associated with Mild Cognitive Impairment (MCI) and Alzheimer's disease…
- Trial name
- NCT01044758
- Testing
- Levetiracetam 62.5mg, Levetiracetam 125mg, Levetiracetam 250mg
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Social Isolation, SCD
The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)
The goal of this clinical trial is to learn about the effects of social isolation and social interaction on the risk of dementia progression and brain function in SCD 1.
- Conditions
- Social Isolation, SCD, Subjective Cognitive Decline, MCI
- Trial name
- NCT06335836
- Testing
- social isolation
- Where
- China
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Alzheimer's Disease
A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560. Side effects and laboratory results will be monitored.
- Trial name
- NCT02754830
- Testing
- LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Aging, Alzheimer's Disease
The Feasibility, Safety and Tolerability of VR-based Audiovisual Stimulation
This single-session, within-subject, sham-controlled early feasibility study evaluated the safety, tolerability, and feasibility of delivering 40 Hz audiovisual (gamma sensory) stimulation through a virtual reality (VR) headset…
- Conditions
- Healthy Aging, Alzheimer's Disease, Mild Cognitive Impairment
- Trial name
- CFS (NCT06234930)
- Testing
- Audiovisual stimulation VR system
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Clarity Health Technologies, Inc
Alzheimer s Disease, Mild Cognitive Impairment
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Background: About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias.
- Conditions
- Alzheimer s Disease, Mild Cognitive Impairment, Healthy
- Trial name
- NCT07169630
- Testing
- 18F-PF974, 18F-florbetaben
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Alzheimer Disease, Late Onset, Mild Cognitive Impairment
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers
To establish the diagnostic and prognostic models that could help the preclinical identification of subjects at higher risk of clinical progression to mild cognitive impairment and dementia based on combined features of baseline…
- Conditions
- Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Subjective Cognitive Decline
- Trial name
- NCT06561906
- Testing
- Multimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
Community-based Screening for Alzheimer's Disease
The goal of this prospective, multicenter, observational cohort study is to evaluate the screening performance of blood-based biomarkers for Alzheimer's disease (AD) in a real-world community screening setting, and to establish…
- Conditions
- Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI), Cognitive Impairment
- Trial name
- CSAD (NCT07570719)
- Testing
- No study-specific intervention
- Where
- 4 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Kuang XiaoJun
Mild Cognitive Impairment, Alzheimer Disease, Late Onset
Multimodal Assesment of Alzheimer Patients
The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD). The main questions the study aims to answer are: 1.
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Late Onset, Cognitive Impairment, Dementia
- Trial name
- MultiAD (NCT06448403)
- Testing
- MRI Scanning, 64-channel EEG, Polysomnography
- Where
- Norway
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology